FDA delays decision on AMAG treatment

FDA delays decision on AMAG treatment

In an SEC filing, AMAG Pharmaceuticals said it received word from the Food and Drug Administration about its application for broader use of its Feraheme injection to treat iron deficiency anemia in adults who cannot use oral iron. The FDA said it

9
Like
Save

Comments

Write a comment

*